Colorectal cancer survival advantage in MUTYH-associated polyposis

November 02, 2010

Survival for colorectal cancer patients with MUTYH-associated polyposis was statistically significantly better than for patients with colorectal cancer from the general population, according to a recent study published online November 2 in The Journal of the National Cancer Institute.

People who inherit a mutation in the MUTYH gene have nearly a 100% risk for developing colon cancer at some point in their lifetimes. But it is unknown whether specific histological and molecular genetic features of cancer associated with this genotype influence tumor behavior and survival.

To determine whether patients with MUTYH-associated polyposis colorectal cancer had different survival rates than control colorectal cancer patients, Maartje Nielsen, M.D., of the Leiden University Medical Center, and colleagues, conducted a multicenter cohort study in Europe that included 147 patients with MUTYH-associated polyposis colorectal cancer and 272 population-based control patients with colorectal cancer. Control and study group patients were matched for country, stage, age and year at diagnosis, and cancer subsite.

The researchers found that survival of patients with MUTYH-associated polyposis colorectal cancer was statistically significantly better than for control patients with colorectal cancer. Their five-year survival rate was 78% compared with 63% for the control group. Survival benefit was higher among patients with stage I and II disease than for those with stage III and IV disease.

The researchers offer a speculation about the better survival rate among the patients with MUTYH-associated polyposis colorectal cancer, compared with the control patients: "A compromised base excision repair system could render MUTYH-associated polyposis colorectal cancer more immunogenic than sporadic colorectal cancers, which are characterized predominantly by chromosomal instability."

In an accompanying editorial, Henry T. Lynch, MD, and Stephen J. Lanspa, MD, of Creighton University, hypothesize that the cancer-causing mutations in MUTYH, as well as in the mismatch repair genes predisposing to Lynch syndrome, are the causal factors for their respective survival advantages. Furthermore, they write, "the ultimate understanding of the pathogenetic pathways elicited by these respective mutations may serve as models for studying both survival and increased virulence of hereditary and sporadic colorectal cancers."
-end-
Contact:

Article: Maartje Nielsen, 01131715266036, M.Nielsen@lumc.nl

Editorial: N. Kathryn Clark, Public Relations Coordinator, Creighton University, 402-280-2864, kathrynclark@creighton.edu

Journal of the National Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.